论文部分内容阅读
浆细胞白血病是一种少见的恶性浆细胞性疾病,约占骨髓瘤总数的1％～2％,原发性浆细胞白血病(PPCL)通常进展迅速,生存期很 短。标准生物碱类药物和激素治疗PPCL生存期短,仅2～6个月;强烈的化疗也仅能诱导约50％患者达缓解,中位生存期约20个月。本研究比较了中等剂量马法兰加地塞米松(M-80)与其他化疗方案治疗PPCL患者的疗效。 方法 初治PPCL共24例,中位年龄64(32～82)岁,男9例,女15例。其外周血浆细胞超过20％或总数超过2×10~9/L,且出现单克隆浆细胞增生。测定血、尿单克隆蛋白;对患者进行
Plasma cell leukemia is a rare malignant plasma cell disease, accounting for about 1% to 2% of the total number of myeloma. Primary plasma cell leukemia (PPCL) usually progresses rapidly and has a short survival period. Standard alkaloids and hormone therapy PPCL short survival, only 2 to 6 months; strong chemotherapy can only lead to about 50% of patients remission, the median survival of about 20 months. This study compared the efficacy of mid-dose melphalan plus dexamethasone (M-80) with other chemotherapy regimens in patients with PPCL. Methods The initial treatment of PPCL 24 cases, the median age 64 (32 to 82) years old, 9 males and 15 females. The peripheral plasma cells more than 20% or more than 2 × 10 ~ 9 / L, and the emergence of monoclonal plasma cell proliferation. Determination of blood, urine monoclonal protein; for patients